KR102338449B1 - 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 - Google Patents
표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 Download PDFInfo
- Publication number
- KR102338449B1 KR102338449B1 KR1020207015382A KR20207015382A KR102338449B1 KR 102338449 B1 KR102338449 B1 KR 102338449B1 KR 1020207015382 A KR1020207015382 A KR 1020207015382A KR 20207015382 A KR20207015382 A KR 20207015382A KR 102338449 B1 KR102338449 B1 KR 102338449B1
- Authority
- KR
- South Korea
- Prior art keywords
- protein
- amino acids
- cas13
- sequence
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract description 66
- 150000007523 nucleic acids Chemical class 0.000 title abstract description 44
- 102000039446 nucleic acids Human genes 0.000 title abstract description 31
- 108020004707 nucleic acids Proteins 0.000 title abstract description 31
- 239000000203 mixture Substances 0.000 title abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 399
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 380
- 102000055025 Adenosine deaminases Human genes 0.000 claims abstract description 182
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims abstract description 181
- 150000001413 amino acids Chemical group 0.000 claims description 580
- 230000035772 mutation Effects 0.000 claims description 215
- 239000012636 effector Substances 0.000 claims description 165
- 210000004027 cell Anatomy 0.000 claims description 86
- 125000003729 nucleotide group Chemical group 0.000 claims description 81
- 239000002773 nucleotide Substances 0.000 claims description 76
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 72
- 210000004899 c-terminal region Anatomy 0.000 claims description 58
- 238000003776 cleavage reaction Methods 0.000 claims description 50
- 230000007017 scission Effects 0.000 claims description 48
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 38
- 229930024421 Adenine Natural products 0.000 claims description 35
- 229960000643 adenine Drugs 0.000 claims description 35
- 238000006481 deamination reaction Methods 0.000 claims description 34
- 230000009615 deamination Effects 0.000 claims description 32
- 102000035181 adaptor proteins Human genes 0.000 claims description 26
- 108091005764 adaptor proteins Proteins 0.000 claims description 26
- 241000282414 Homo sapiens Species 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 12
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 241000238366 Cephalopoda Species 0.000 claims description 7
- 241000611831 Prevotella sp. Species 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 3
- 108010035533 Drosophila Proteins Proteins 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 101100123845 Aphanizomenon flos-aquae (strain 2012/KM1/D3) hepT gene Proteins 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 abstract description 88
- 230000003197 catalytic effect Effects 0.000 abstract description 46
- 235000001014 amino acid Nutrition 0.000 description 611
- 229940024606 amino acid Drugs 0.000 description 584
- 235000018102 proteins Nutrition 0.000 description 329
- 229920002477 rna polymer Polymers 0.000 description 101
- 230000000694 effects Effects 0.000 description 91
- 102000005381 Cytidine Deaminase Human genes 0.000 description 84
- 108010031325 Cytidine deaminase Proteins 0.000 description 84
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 79
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 76
- 102000004190 Enzymes Human genes 0.000 description 74
- 108090000790 Enzymes Proteins 0.000 description 74
- 229940088598 enzyme Drugs 0.000 description 73
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 72
- 230000000875 corresponding effect Effects 0.000 description 69
- 108091033409 CRISPR Proteins 0.000 description 67
- 125000005647 linker group Chemical group 0.000 description 64
- 230000027455 binding Effects 0.000 description 57
- 102000053602 DNA Human genes 0.000 description 54
- 108020004414 DNA Proteins 0.000 description 54
- 238000010357 RNA editing Methods 0.000 description 50
- 230000026279 RNA modification Effects 0.000 description 50
- 238000010354 CRISPR gene editing Methods 0.000 description 48
- 239000000758 substrate Substances 0.000 description 44
- 238000002604 ultrasonography Methods 0.000 description 38
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 35
- 108020005004 Guide RNA Proteins 0.000 description 35
- 101710163270 Nuclease Proteins 0.000 description 35
- 229960005305 adenosine Drugs 0.000 description 35
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 35
- 239000003112 inhibitor Substances 0.000 description 34
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 33
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 33
- 108060001084 Luciferase Proteins 0.000 description 32
- 239000005089 Luciferase Substances 0.000 description 32
- 108091023037 Aptamer Proteins 0.000 description 31
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 31
- 230000033590 base-excision repair Effects 0.000 description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 description 28
- 230000001965 increasing effect Effects 0.000 description 28
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 description 26
- 102000012758 APOBEC-1 Deaminase Human genes 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 26
- 230000004048 modification Effects 0.000 description 26
- 238000012986 modification Methods 0.000 description 26
- 230000005684 electric field Effects 0.000 description 25
- 238000013461 design Methods 0.000 description 24
- 230000006870 function Effects 0.000 description 24
- 230000004927 fusion Effects 0.000 description 24
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 23
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 23
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 23
- 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 description 22
- 238000003197 gene knockdown Methods 0.000 description 22
- 125000000539 amino acid group Chemical group 0.000 description 21
- 102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 description 20
- 108020004705 Codon Proteins 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 19
- 108091033319 polynucleotide Proteins 0.000 description 19
- 235000021251 pulses Nutrition 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 18
- 238000011002 quantification Methods 0.000 description 17
- 239000004475 Arginine Substances 0.000 description 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 16
- 230000000295 complement effect Effects 0.000 description 16
- 229940104302 cytosine Drugs 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 15
- 230000001939 inductive effect Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 102100024364 Disintegrin and metalloproteinase domain-containing protein 8 Human genes 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 13
- 229930010555 Inosine Natural products 0.000 description 13
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 13
- -1 PspCas13b Proteins 0.000 description 13
- 229960003786 inosine Drugs 0.000 description 13
- 238000012384 transportation and delivery Methods 0.000 description 13
- 102100039128 DNA-3-methyladenine glycosylase Human genes 0.000 description 12
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 12
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 12
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 12
- 238000004422 calculation algorithm Methods 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000007385 chemical modification Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 108010034927 3-methyladenine-DNA glycosylase Proteins 0.000 description 9
- 101710159080 Aconitate hydratase A Proteins 0.000 description 9
- 101710159078 Aconitate hydratase B Proteins 0.000 description 9
- 101000860104 Leptotrichia wadei (strain F0279) CRISPR-associated endoribonuclease Cas13a Proteins 0.000 description 9
- 101710105008 RNA-binding protein Proteins 0.000 description 9
- 108091027967 Small hairpin RNA Proteins 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000007481 next generation sequencing Methods 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 230000009437 off-target effect Effects 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000008439 repair process Effects 0.000 description 9
- 239000004055 small Interfering RNA Substances 0.000 description 9
- 125000006850 spacer group Chemical group 0.000 description 9
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 9
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 108010004483 APOBEC-3G Deaminase Proteins 0.000 description 8
- 102000002797 APOBEC-3G Deaminase Human genes 0.000 description 8
- 241000093740 Acidaminococcus sp. Species 0.000 description 8
- 108091079001 CRISPR RNA Proteins 0.000 description 8
- 102000000331 Double-stranded RNA-binding domains Human genes 0.000 description 8
- 108050008793 Double-stranded RNA-binding domains Proteins 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 101000755690 Homo sapiens Single-stranded DNA cytosine deaminase Proteins 0.000 description 8
- 102000040945 Transcription factor Human genes 0.000 description 8
- 108091023040 Transcription factor Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 241000186394 Eubacterium Species 0.000 description 7
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 7
- 241000605894 Porphyromonas Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 102000043770 human ADAR Human genes 0.000 description 7
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 7
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 239000004144 Ethoxylated Mono- and Di-Glyceride Substances 0.000 description 6
- 241000589602 Francisella tularensis Species 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 101000742736 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3G Proteins 0.000 description 6
- 101000611202 Homo sapiens Peptidyl-prolyl cis-trans isomerase B Proteins 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 6
- 241000605861 Prevotella Species 0.000 description 6
- 238000003559 RNA-seq method Methods 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- UHDGCWIWMRVCDJ-XVFCMESISA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 6
- 238000010362 genome editing Methods 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 102000054962 human APOBEC3G Human genes 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000000051 modifying effect Effects 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 6
- 229940035893 uracil Drugs 0.000 description 6
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 5
- 241000604451 Acidaminococcus Species 0.000 description 5
- 101710132601 Capsid protein Proteins 0.000 description 5
- 101710094648 Coat protein Proteins 0.000 description 5
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 5
- 230000007018 DNA scission Effects 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 241000589601 Francisella Species 0.000 description 5
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 5
- 241000589902 Leptospira Species 0.000 description 5
- 241001148627 Leptospira inadai Species 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108700011259 MicroRNAs Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108020004485 Nonsense Codon Proteins 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 241000878522 Porphyromonas crevioricanis Species 0.000 description 5
- 101710083689 Probable capsid protein Proteins 0.000 description 5
- 108091028664 Ribonucleotide Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 102000015694 estrogen receptors Human genes 0.000 description 5
- 108010038795 estrogen receptors Proteins 0.000 description 5
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000002028 premature Effects 0.000 description 5
- 239000002336 ribonucleotide Substances 0.000 description 5
- 125000002652 ribonucleotide group Chemical group 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 102100034215 AFG3-like protein 2 Human genes 0.000 description 4
- 241001147780 Alicyclobacillus Species 0.000 description 4
- 241000605059 Bacteroidetes Species 0.000 description 4
- 241000168061 Butyrivibrio proteoclasticus Species 0.000 description 4
- 102220613440 Casein kinase II subunit alpha 3_D917A_mutation Human genes 0.000 description 4
- 102220613443 Casein kinase II subunit alpha 3_E1006A_mutation Human genes 0.000 description 4
- 241000193403 Clostridium Species 0.000 description 4
- 108010080611 Cytosine Deaminase Proteins 0.000 description 4
- 102000000311 Cytosine Deaminase Human genes 0.000 description 4
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 101000780591 Homo sapiens AFG3-like protein 2 Proteins 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 241000589248 Legionella Species 0.000 description 4
- 208000007764 Legionnaires' Disease Diseases 0.000 description 4
- 241000186779 Listeria monocytogenes Species 0.000 description 4
- 241000588653 Neisseria Species 0.000 description 4
- 241001302521 Prevotella albensis Species 0.000 description 4
- 241001135219 Prevotella disiens Species 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 239000005547 deoxyribonucleotide Substances 0.000 description 4
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229940118764 francisella tularensis Drugs 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000030648 nucleus localization Effects 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 230000009897 systematic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000589941 Azospirillum Species 0.000 description 3
- 241000589876 Campylobacter Species 0.000 description 3
- 241000206594 Carnobacterium Species 0.000 description 3
- 102220613830 Casein kinase II subunit alpha 3_D1255A_mutation Human genes 0.000 description 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 3
- 241000193163 Clostridioides difficile Species 0.000 description 3
- 102100026280 Cryptochrome-2 Human genes 0.000 description 3
- 101710119767 Cryptochrome-2 Proteins 0.000 description 3
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 3
- 101710096438 DNA-binding protein Proteins 0.000 description 3
- 241000936939 Desulfonatronum Species 0.000 description 3
- 241000605716 Desulfovibrio Species 0.000 description 3
- 102100020743 Dipeptidase 1 Human genes 0.000 description 3
- 108090000204 Dipeptidase 1 Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241001430278 Helcococcus Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000186781 Listeria Species 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 241000589323 Methylobacterium Species 0.000 description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 241000135938 Nitratifractor Species 0.000 description 3
- 241000740708 Paludibacter Species 0.000 description 3
- 108020005067 RNA Splice Sites Proteins 0.000 description 3
- 108091008103 RNA aptamers Proteins 0.000 description 3
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 3
- 230000004570 RNA-binding Effects 0.000 description 3
- 241000191025 Rhodobacter Species 0.000 description 3
- 241000605947 Roseburia Species 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 241001147687 Staphylococcus auricularis Species 0.000 description 3
- 241000191965 Staphylococcus carnosus Species 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 241000605261 Thiomicrospira Species 0.000 description 3
- 241000670722 Tuberibacillus Species 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 230000005670 electromagnetic radiation Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002632 lipids Chemical group 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000037434 nonsense mutation Effects 0.000 description 3
- 230000000541 pulsatile effect Effects 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 2
- MZZYGYNZAOVRTG-UHFFFAOYSA-N 2-hydroxy-n-(1h-1,2,4-triazol-5-yl)benzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=NN1 MZZYGYNZAOVRTG-UHFFFAOYSA-N 0.000 description 2
- ZLHLYESIHSHXGM-UHFFFAOYSA-N 4,6-dimethyl-1h-imidazo[1,2-a]purin-9-one Chemical compound N=1C(C)=CN(C2=O)C=1N(C)C1=C2NC=N1 ZLHLYESIHSHXGM-UHFFFAOYSA-N 0.000 description 2
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 2
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 2
- 241001588186 Acidaminococcus sp. BV3L6 Species 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 108010052875 Adenine deaminase Proteins 0.000 description 2
- 101000758020 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized aminotransferase BpOF4_10225 Proteins 0.000 description 2
- 241000269350 Anura Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000555281 Brevibacillus Species 0.000 description 2
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 description 2
- 102100032216 Calcium and integrin-binding protein 1 Human genes 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 102220613831 Casein kinase II subunit alpha 3_D1227A_mutation Human genes 0.000 description 2
- 102220613827 Casein kinase II subunit alpha 3_E1028A_mutation Human genes 0.000 description 2
- 102220613941 Casein kinase II subunit alpha 3_R1226A_mutation Human genes 0.000 description 2
- 101000744710 Clostridium pasteurianum Uncharacterized glutaredoxin-like 8.6 kDa protein in rubredoxin operon Proteins 0.000 description 2
- 241000193449 Clostridium tetani Species 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- 108010020076 Cytochrome P-450 CYP2B1 Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 102100040264 DNA dC->dU-editing enzyme APOBEC-3D Human genes 0.000 description 2
- 101710096830 DNA-3-methyladenine glycosylase Proteins 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 101100490452 Drosophila melanogaster Adat1 gene Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 101000653283 Enterobacteria phage T4 Uncharacterized 11.5 kDa protein in Gp31-cd intergenic region Proteins 0.000 description 2
- 101000618324 Enterobacteria phage T4 Uncharacterized 7.9 kDa protein in mobB-Gp55 intergenic region Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 102000018825 Fanconi Anemia Complementation Group C protein Human genes 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000032681 Gluconacetobacter Species 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000964330 Homo sapiens C->U-editing enzyme APOBEC-1 Proteins 0.000 description 2
- 101000943475 Homo sapiens Calcium and integrin-binding protein 1 Proteins 0.000 description 2
- 101000907924 Homo sapiens Centromere protein J Proteins 0.000 description 2
- 101000964382 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3D Proteins 0.000 description 2
- 101001117010 Homo sapiens Pericentrin Proteins 0.000 description 2
- 101000658622 Homo sapiens Testis-specific Y-encoded-like protein 2 Proteins 0.000 description 2
- 101000807859 Homo sapiens Vasopressin V2 receptor Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 241000186780 Listeria ivanovii Species 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 2
- 101100462611 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) prr-1 gene Proteins 0.000 description 2
- 241000135933 Nitratifractor salsuginis Species 0.000 description 2
- 241000135923 Nitratiruptor tergarcus Species 0.000 description 2
- 102000002488 Nucleoplasmin Human genes 0.000 description 2
- 102100024315 Pericentrin Human genes 0.000 description 2
- 241000162745 Porphyromonas gulae Species 0.000 description 2
- 241001135241 Porphyromonas macacae Species 0.000 description 2
- 241000709748 Pseudomonas phage PRR1 Species 0.000 description 2
- 229930185560 Pseudouridine Natural products 0.000 description 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 2
- 101000961876 Pyrococcus woesei Uncharacterized protein in gap 3'region Proteins 0.000 description 2
- 230000007022 RNA scission Effects 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 101001056915 Saccharopolyspora erythraea 6-deoxyerythronolide-B synthase EryA2, modules 3 and 4 Proteins 0.000 description 2
- 201000000114 Seckel syndrome 4 Diseases 0.000 description 2
- 206010048676 Sjogren-Larsson Syndrome Diseases 0.000 description 2
- 101000819248 Staphylococcus aureus Uncharacterized protein in ileS 5'region Proteins 0.000 description 2
- 241000264435 Streptococcus dysgalactiae subsp. equisimilis Species 0.000 description 2
- 241000194023 Streptococcus sanguinis Species 0.000 description 2
- 241000255588 Tephritidae Species 0.000 description 2
- 102100034917 Testis-specific Y-encoded-like protein 2 Human genes 0.000 description 2
- 241000605257 Thiomicrospira sp. Species 0.000 description 2
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 208000014769 Usher Syndromes Diseases 0.000 description 2
- 102100037108 Vasopressin V2 receptor Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000037006 agalactosis Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 241000510314 bacterium MA2020 Species 0.000 description 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 101150000705 cas1 gene Proteins 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 108020001778 catalytic domains Proteins 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004913 chyme Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000012237 germline editing Methods 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 102000044898 human ADARB1 Human genes 0.000 description 2
- 102000046390 human APOBEC1 Human genes 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 208000036546 leukodystrophy Diseases 0.000 description 2
- 201000006905 long QT syndrome 2 Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 108060005597 nucleoplasmin Proteins 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000001012 protector Effects 0.000 description 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- BAAVRTJSLCSMNM-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 BAAVRTJSLCSMNM-CMOCDZPBSA-N 0.000 description 1
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 1
- JLIDBLDQVAYHNE-LXGGSRJLSA-N 2-cis-abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\C1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-LXGGSRJLSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 1
- 102100032578 Adenosine deaminase domain-containing protein 1 Human genes 0.000 description 1
- 102100032577 Adenosine deaminase domain-containing protein 2 Human genes 0.000 description 1
- 108700040115 Adenosine deaminases Proteins 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100040399 C->U-editing enzyme APOBEC-2 Human genes 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100490563 Caenorhabditis elegans adr-1 gene Proteins 0.000 description 1
- 101100388220 Caenorhabditis elegans adr-2 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241001502303 Candidatus Methanoplasma Species 0.000 description 1
- 241001040999 Candidatus Methanoplasma termitum Species 0.000 description 1
- 241000223282 Candidatus Peregrinibacteria Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102220614002 Casein kinase II subunit alpha 3_S1228A_mutation Human genes 0.000 description 1
- QPRMGHKASRLPJP-KZNAEPCWSA-N Cassine Natural products C[C@H]1N[C@H](CCCCCCCCCCC(C)=O)CC[C@H]1O QPRMGHKASRLPJP-KZNAEPCWSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102100040263 DNA dC->dU-editing enzyme APOBEC-3A Human genes 0.000 description 1
- 102100040262 DNA dC->dU-editing enzyme APOBEC-3B Human genes 0.000 description 1
- 102100040261 DNA dC->dU-editing enzyme APOBEC-3C Human genes 0.000 description 1
- 102100040266 DNA dC->dU-editing enzyme APOBEC-3F Human genes 0.000 description 1
- 102100038050 DNA dC->dU-editing enzyme APOBEC-3H Human genes 0.000 description 1
- 101710082737 DNA dC->dU-editing enzyme APOBEC-3H Proteins 0.000 description 1
- 238000010442 DNA editing Methods 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 108010060616 DNA-3-methyladenine glycosidase II Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 241001653748 Doryteuthis pealeii Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101100219622 Escherichia coli (strain K12) casC gene Proteins 0.000 description 1
- 101100326871 Escherichia coli (strain K12) ygbF gene Proteins 0.000 description 1
- 101100438439 Escherichia coli (strain K12) ygbT gene Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 1
- 241000449741 Francisella cf. novicida Fx1 Species 0.000 description 1
- 241000588088 Francisella tularensis subsp. novicida U112 Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010041896 GTYRAC-specific type II deoxyribonucleases Proteins 0.000 description 1
- 241000963438 Gaussia <copepod> Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229940123611 Genome editing Drugs 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000797006 Homo sapiens Adenosine deaminase domain-containing protein 1 Proteins 0.000 description 1
- 101000796996 Homo sapiens Adenosine deaminase domain-containing protein 2 Proteins 0.000 description 1
- 101000964322 Homo sapiens C->U-editing enzyme APOBEC-2 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000964378 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3A Proteins 0.000 description 1
- 101000964385 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3B Proteins 0.000 description 1
- 101000964383 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3C Proteins 0.000 description 1
- 101000964377 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3F Proteins 0.000 description 1
- 101000800426 Homo sapiens Putative C->U-editing enzyme APOBEC-4 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 1
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000256602 Isoptera Species 0.000 description 1
- 101150049925 Kcna1 gene Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001134638 Lachnospira Species 0.000 description 1
- 241001112693 Lachnospiraceae Species 0.000 description 1
- 241000904817 Lachnospiraceae bacterium Species 0.000 description 1
- 241000448224 Lachnospiraceae bacterium MA2020 Species 0.000 description 1
- 241000448225 Lachnospiraceae bacterium MC2017 Species 0.000 description 1
- 241000689670 Lachnospiraceae bacterium ND2006 Species 0.000 description 1
- 208000004609 Leber congenital amaurosis 10 Diseases 0.000 description 1
- 241001453171 Leptotrichia Species 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241001193016 Moraxella bovoculi 237 Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000777691 Mus musculus Cytidine and dCMP deaminase domain-containing protein 1 Proteins 0.000 description 1
- 101000912065 Mus musculus Cytidine deaminase Proteins 0.000 description 1
- 101100078999 Mus musculus Mx1 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical class C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- 102220506341 N-alpha-acetyltransferase 40_W90A_mutation Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108010066154 Nuclear Export Signals Proteins 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000936936 Opitutaceae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000193465 Paeniclostridium sordellii Species 0.000 description 1
- 241000182952 Parcubacteria group bacterium GW2011_GWC2_44_17 Species 0.000 description 1
- 241001386753 Parvibaculum Species 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 241000251745 Petromyzon marinus Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000711943 Porphyromonadaceae bacterium Species 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000004777 Primary Hyperoxaluria Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102000017742 Pumilio homology domains Human genes 0.000 description 1
- 108050005947 Pumilio homology domains Proteins 0.000 description 1
- 102100033091 Putative C->U-editing enzyme APOBEC-4 Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241001478212 Riemerella anatipestifer Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241001037426 Smithella sp. Species 0.000 description 1
- 241000949716 Sphaerochaeta Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 101100166147 Streptococcus thermophilus cas9 gene Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- 101100329497 Thermoproteus tenax (strain ATCC 35583 / DSM 2078 / JCM 9277 / NBRC 100435 / Kra 1) cas2 gene Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102100026260 Titin Human genes 0.000 description 1
- 241000283907 Tragelaphus oryx Species 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 241001389010 Tuta Species 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241001531273 [Eubacterium] eligens Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000019905 acrocephalosyndactyly Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- MOVRNJGDXREIBM-UHFFFAOYSA-N aid-1 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C(O)C1 MOVRNJGDXREIBM-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 102000009899 alpha Karyopherins Human genes 0.000 description 1
- 108010077099 alpha Karyopherins Proteins 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 206010001902 amaurosis Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 241000512513 bacterium MC2017 Species 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 101150006308 botA gene Proteins 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 101150117416 cas2 gene Proteins 0.000 description 1
- 101150111685 cas4 gene Proteins 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 108010031180 cypridina luciferase Proteins 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000003060 endolymph Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 108020004067 estrogen-related receptors Proteins 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 201000007514 familial adenomatous polyposis 1 Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 201000004543 glycogen storage disease III Diseases 0.000 description 1
- 108010033706 glycylserine Proteins 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 108700032552 influenza virus INS1 Proteins 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 210000004049 perilymph Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Chemical group 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 101150075675 tatC gene Proteins 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108010032276 tyrosyl-glutamyl-tyrosyl-glutamic acid Proteins 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04005—Cytidine deaminase (3.5.4.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04004—Adenosine deaminase (3.5.4.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561669P | 2017-09-21 | 2017-09-21 | |
| US62/561,669 | 2017-09-21 | ||
| PCT/US2018/052247 WO2019060746A1 (en) | 2017-09-21 | 2018-09-21 | SYSTEMS, METHODS, AND COMPOSITIONS FOR THE TARGETED EDITING OF NUCLEIC ACIDS |
| KR1020207008394A KR20200066616A (ko) | 2017-09-21 | 2018-09-21 | 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207008394A Division KR20200066616A (ko) | 2017-09-21 | 2018-09-21 | 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200064168A KR20200064168A (ko) | 2020-06-05 |
| KR102338449B1 true KR102338449B1 (ko) | 2021-12-10 |
Family
ID=65810620
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207015382A Active KR102338449B1 (ko) | 2017-09-21 | 2018-09-21 | 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 |
| KR1020207008394A Ceased KR20200066616A (ko) | 2017-09-21 | 2018-09-21 | 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207008394A Ceased KR20200066616A (ko) | 2017-09-21 | 2018-09-21 | 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11618896B2 (enExample) |
| EP (1) | EP3684397A4 (enExample) |
| JP (4) | JP2020535802A (enExample) |
| KR (2) | KR102338449B1 (enExample) |
| CN (1) | CN111511388A (enExample) |
| AU (4) | AU2018338318B2 (enExample) |
| CA (1) | CA3073848A1 (enExample) |
| WO (1) | WO2019060746A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025048512A1 (ko) * | 2023-08-30 | 2025-03-06 | 주식회사 제노헬릭스 | 제한효소를 이용한 rna 라이브러리 제작 방법 |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2930643T3 (es) | 2015-11-23 | 2022-12-20 | Univ California | Seguimiento y manipulación de ARN celular a través de la administración nuclear de CRISPR/CAS9 |
| EP3622062A4 (en) | 2017-05-10 | 2020-10-14 | The Regents of the University of California | DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9 |
| KR102338449B1 (ko) * | 2017-09-21 | 2021-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 |
| US12221636B2 (en) * | 2017-10-04 | 2025-02-11 | The Broad Institute, Inc. | Systems methods, and compositions for targeted nucleic acid editing |
| EP3701025A4 (en) * | 2017-10-23 | 2021-07-28 | The Broad Institute, Inc. | NUCLEIC ACID TARGETED EDITING SYSTEMS, METHODS AND COMPOSITIONS |
| WO2019084063A1 (en) * | 2017-10-23 | 2019-05-02 | The Broad Institute, Inc. | SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION |
| WO2019104094A2 (en) * | 2017-11-21 | 2019-05-31 | The Regents Of The University Of California | Fusion proteins and methods for site-directed genome editing |
| JP7344300B2 (ja) | 2018-09-18 | 2023-09-13 | ブイエヌブイ ニューコ インク． | Ａｒｃベースのカプシドおよびその使用 |
| CN116042611A (zh) * | 2018-10-12 | 2023-05-02 | 北京大学 | 编辑rna的方法和组合物 |
| US12258594B2 (en) | 2018-12-05 | 2025-03-25 | The Broad Institute, Inc. | Cas proteins with reduced immunogenicity and methods of screening thereof |
| CA3127243A1 (en) | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| WO2020154343A1 (en) | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| CA3126947A1 (en) | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| WO2020172343A2 (en) | 2019-02-19 | 2020-08-27 | Massachusetts Institute Of Technology | Methods for treating injuries |
| US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| WO2020186237A1 (en) | 2019-03-13 | 2020-09-17 | The Broad Institute, Inc. | Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof |
| US20220143148A1 (en) | 2019-03-14 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells |
| EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| US20220152148A1 (en) | 2019-03-18 | 2022-05-19 | The Broad Institute, Inc. | Modulation of type 2 immunity by targeting clec-2 signaling |
| EP3947687A1 (en) | 2019-03-29 | 2022-02-09 | Massachusetts Institute of Technology | Constructs for continuous monitoring of live cells |
| TW202043249A (zh) | 2019-04-15 | 2020-12-01 | 大陸商博雅輯因（北京）生物科技有限公司 | 編輯rna的方法和組合物 |
| WO2020214830A1 (en) * | 2019-04-16 | 2020-10-22 | The Regents Of The University Of California | Protein translational control |
| US20220249701A1 (en) | 2019-05-14 | 2022-08-11 | The Broad Institute, Inc. | Compositions and methods for targeting multinucleated cells |
| WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| US20220243178A1 (en) | 2019-05-31 | 2022-08-04 | The Broad Institute, Inc. | Methods for treating metabolic disorders by targeting adcy5 |
| JP2022536173A (ja) * | 2019-06-13 | 2022-08-12 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | シチジンアナログを含むアンチセンスｒｎａ編集オリゴヌクレオチド |
| US20220243194A1 (en) | 2019-07-12 | 2022-08-04 | Peking University | Targeted rna editing by leveraging endogenous adar using engineered rnas |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| US12195723B2 (en) | 2019-11-08 | 2025-01-14 | The Broad Institute, Inc. | Engineered antigen presenting cells and uses thereof |
| US12241830B2 (en) | 2019-12-06 | 2025-03-04 | Broad Institute, Inc. | Living biosensors |
| WO2021146641A1 (en) | 2020-01-17 | 2021-07-22 | The Broad Institute, Inc. | Small type ii-d cas proteins and methods of use thereof |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| WO2021169980A1 (en) * | 2020-02-25 | 2021-09-02 | Shanghaitech University | Compositions and methods for detecting nucleic acid-protein interactions |
| CA3180019A1 (en) * | 2020-04-15 | 2021-10-21 | Edigene Therapeutics (Beijing) Inc. | Method and drug for treating hurler syndrome |
| EP4150087A1 (en) * | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
| WO2021231830A1 (en) * | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of abca4 |
| EP4150090A1 (en) * | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
| US20210380980A1 (en) * | 2020-05-28 | 2021-12-09 | Korro Bio, Inc. | Methods and Compositions for the ADAR-Mediated Editing of SERPINA1 |
| EP4172336A4 (en) * | 2020-06-29 | 2024-07-24 | Bar Ilan University | Composition and methods for identifying antisense guide rna for rna editing |
| WO2022020431A2 (en) * | 2020-07-21 | 2022-01-27 | Trustees Of Boston University | Inducible control of gene expression |
| AU2021321586A1 (en) | 2020-08-07 | 2023-03-16 | Dana-Farber Cancer Institute, Inc. | Therapeutic targeting of phosphate dysregulation in cancer via the XPR1:KIDINS220 protein complex |
| CA3190991A1 (en) | 2020-09-02 | 2022-03-10 | Omar Abudayyeh | Systems, methods, and compositions for rna-guided rna-targeting crispr effectors |
| EP4253540A4 (en) * | 2020-11-30 | 2025-09-10 | Univ Niigata | ANTISENSE NUCLEIC ACID AND ITS USE |
| KR102685590B1 (ko) * | 2020-12-01 | 2024-07-17 | 한양대학교 산학협력단 | 사이토신 교정 활성이 제거된 아데닌 염기교정 유전자가위 및 이의 용도 |
| CN114958920A (zh) * | 2021-02-25 | 2022-08-30 | 北京中因科技有限公司 | 一种新型CRISPR-Cas9系统载体及其制备方法和应用 |
| CN112892891B (zh) * | 2021-03-03 | 2022-12-06 | 武汉伯瑞恒医药科技有限公司 | 一种抗白血病活性分子及中间体提取用离心装置 |
| US12260938B2 (en) * | 2021-03-19 | 2025-03-25 | Heritable Agriculture Inc. | Machine learning driven gene discovery and gene editing in plants |
| WO2023024504A1 (en) * | 2021-08-22 | 2023-03-02 | Huigene Therapeutics Co., Ltd. | Crispr-cas13 system for treating sod1-associated diseases |
| WO2023112048A1 (en) * | 2021-12-13 | 2023-06-22 | Indian Institute Of Science | Crispr-dcas13 system, composition, and method to induce translational readthrough across stop codons |
| WO2023144104A1 (en) * | 2022-01-25 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Base editing approaches for the treatment of βeta-thalassemia |
| CN119562762A (zh) | 2022-04-04 | 2025-03-04 | 加利福尼亚大学董事会 | 遗传互补组合物和方法 |
| AU2023358764A1 (en) * | 2022-10-14 | 2025-04-17 | Spark Therapeutics, Inc. | Gene editing for controlled expression of episomal genes |
| WO2024192141A1 (en) | 2023-03-13 | 2024-09-19 | Dana-Farber Cancer Institute, Inc. | Treatment of cancers having a drug-resistant mesenchymal cell state |
| WO2024197185A1 (en) | 2023-03-21 | 2024-09-26 | The Broad Institute, Inc. | Methods and compositions for dissecting organelle physiology |
| WO2025015176A1 (en) * | 2023-07-11 | 2025-01-16 | University Of Florida Research Foundation, Incorporated | Efficient transgene-free genome editing in plants in the t0 generation based on a co-editing strategy |
| CN116875633B (zh) * | 2023-09-06 | 2023-11-24 | 北京首佳利华科技有限公司 | 雄性不育基因ZmSWEET6及其在创制玉米雄性不育系中的应用 |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025137549A1 (en) * | 2023-12-20 | 2025-06-26 | Regents Of The University Of Minnesota | Wheat dwarf india virus plant gene engineering system |
| WO2025250808A1 (en) | 2024-05-29 | 2025-12-04 | The Brigham And Women’S Hospital, Inc. | Anti-crispr delivery compositions and methods |
| CN118546935B (zh) * | 2024-07-25 | 2024-10-22 | 深圳大学 | 一种基于干扰或敲除人pcsk9基因制备增强型car-t细胞的方法及应用 |
| CN118901668A (zh) * | 2024-09-04 | 2024-11-08 | 青岛农业大学 | 一种pgam2在布莱凯特黑牛育种中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170211142A1 (en) | 2015-10-22 | 2017-07-27 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
Family Cites Families (313)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4535060A (en) | 1983-01-05 | 1985-08-13 | Calgene, Inc. | Inhibition resistant 5-enolpyruvyl-3-phosphoshikimate synthetase, production and use |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4940835A (en) | 1985-10-29 | 1990-07-10 | Monsanto Company | Glyphosate-resistant plants |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| DE3765449D1 (de) | 1986-03-11 | 1990-11-15 | Plant Genetic Systems Nv | Durch gentechnologie erhaltene und gegen glutaminsynthetase-inhibitoren resistente pflanzenzellen. |
| US4975374A (en) | 1986-03-18 | 1990-12-04 | The General Hospital Corporation | Expression of wild type and mutant glutamine synthetase in foreign hosts |
| ATE141646T1 (de) | 1986-04-09 | 1996-09-15 | Genzyme Corp | Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern |
| US5273894A (en) | 1986-08-23 | 1993-12-28 | Hoechst Aktiengesellschaft | Phosphinothricin-resistance gene, and its use |
| US5637489A (en) | 1986-08-23 | 1997-06-10 | Hoechst Aktiengesellschaft | Phosphinothricin-resistance gene, and its use |
| US5276268A (en) | 1986-08-23 | 1994-01-04 | Hoechst Aktiengesellschaft | Phosphinothricin-resistance gene, and its use |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| EP0333033A1 (en) | 1988-03-09 | 1989-09-20 | Meiji Seika Kaisha Ltd. | Glutamine synthesis gene and glutamine synthetase |
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6013861A (en) | 1989-05-26 | 2000-01-11 | Zeneca Limited | Plants and processes for obtaining them |
| US5908810A (en) | 1990-02-02 | 1999-06-01 | Hoechst Schering Agrevo Gmbh | Method of improving the growth of crop plants which are resistant to glutamine synthetase inhibitors |
| US5739082A (en) | 1990-02-02 | 1998-04-14 | Hoechst Schering Agrevo Gmbh | Method of improving the yield of herbicide-resistant crop plants |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5633435A (en) | 1990-08-31 | 1997-05-27 | Monsanto Company | Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases |
| US5266317A (en) | 1990-10-04 | 1993-11-30 | University Of Georgia Research Foundation, Inc. | Insect-specific paralytic neurotoxin genes for use in biological insect control: methods and compositions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| DE4104782B4 (de) | 1991-02-13 | 2006-05-11 | Bayer Cropscience Gmbh | Neue Plasmide, enthaltend DNA-Sequenzen, die Veränderungen der Karbohydratkonzentration und Karbohydratzusammensetzung in Pflanzen hervorrufen, sowie Pflanzen und Pflanzenzellen enthaltend dieses Plasmide |
| GB9104617D0 (en) | 1991-03-05 | 1991-04-17 | Nickerson Int Seed | Pest control |
| US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
| US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| IL101147A (en) | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| GB9114259D0 (en) | 1991-07-02 | 1991-08-21 | Ici Plc | Plant derived enzyme and dna sequences |
| GB9115909D0 (en) | 1991-07-23 | 1991-09-04 | Nickerson Int Seed | Recombinant dna |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| DK39692D0 (da) | 1992-03-25 | 1992-03-25 | Danisco | Biologisk materiale |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| HUT70467A (en) | 1992-07-27 | 1995-10-30 | Pioneer Hi Bred Int | An improved method of agrobactenium-mediated transformation of cultvred soyhean cells |
| DE4227061A1 (de) | 1992-08-12 | 1994-02-17 | Inst Genbiologische Forschung | DNA-Sequenzen, die in der Pflanze die Bildung von Polyfructanen (Lävanen) hervorrufen, Plasmide enthaltend diese Sequenzen sowie Verfahren zur Herstellung transgener Pflanzen |
| GB9218185D0 (en) | 1992-08-26 | 1992-10-14 | Ici Plc | Novel plants and processes for obtaining them |
| AU690517B2 (en) | 1992-10-14 | 1998-04-30 | Syngenta Limited | Novel plants and processes for obtaining them |
| GB9223454D0 (en) | 1992-11-09 | 1992-12-23 | Ici Plc | Novel plants and processes for obtaining them |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5789156A (en) | 1993-06-14 | 1998-08-04 | Basf Ag | Tetracycline-regulated transcriptional inhibitors |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| WO1995004826A1 (en) | 1993-08-09 | 1995-02-16 | Institut Für Genbiologische Forschung Berlin Gmbh | Debranching enzymes and dna sequences coding them, suitable for changing the degree of branching of amylopectin starch in plants |
| DE4330960C2 (de) | 1993-09-09 | 2002-06-20 | Aventis Cropscience Gmbh | Kombination von DNA-Sequenzen, die in Pflanzenzellen und Pflanzen die Bildung hochgradig amylosehaltiger Stärke ermöglichen, Verfahren zur Herstellung dieser Pflanzen und die daraus erhaltbare modifizierte Stärke |
| CA2176109A1 (en) | 1993-11-09 | 1995-05-18 | Perry Girard Caimi | Transgenic fructan accumulating crops and methods for their production |
| WO1995026407A1 (en) | 1994-03-25 | 1995-10-05 | National Starch And Chemical Investment Holding Corporation | Method for producing altered starch from potato plants |
| RU2201963C2 (ru) | 1994-05-18 | 2003-04-10 | Плант Тек Биотехнологи Гмбх Форшунг Унд Энтвиклунг | ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), РЕКОМБИНАНТНАЯ ДНК, ПРОТЕИН, СПОСОБ ПОЛУЧЕНИЯ ПРОТЕИНА, СПОСОБ ПОЛУЧЕНИЯ МИКРООРГАНИЗМОВ, СПОСОБ ПОЛУЧЕНИЯ КЛЕТОК ГРИБА, СПОСОБ ПОЛУЧЕНИЯ ЛИНЕЙНЫХ α-1,4-ГЛЮКАНОВ И/ИЛИ ФРУКТОЗЫ И СПОСОБ ПОЛУЧЕНИЯ ЛИНЕЙНЫХ α-1,4-ГЛЮКАНОВ И/ИЛИ ФРУКТОЗЫ IN VITRO |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| EP0802720A4 (en) | 1994-06-21 | 1999-01-13 | Zeneca Ltd | NEW PLANTS AND METHOD FOR THEIR PRODUCTION |
| US5824790A (en) | 1994-06-21 | 1998-10-20 | Zeneca Limited | Modification of starch synthesis in plants |
| NL1000064C1 (nl) | 1994-07-08 | 1996-01-08 | Stichting Scheikundig Onderzoe | Produktie van oligosacchariden in transgene planten. |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| DE4441408A1 (de) | 1994-11-10 | 1996-05-15 | Inst Genbiologische Forschung | DNA-Sequenzen aus Solanum tuberosum kodierend Enzyme, die an der Stärkesynthese beteiligt sind, Plasmide, Bakterien, Pflanzenzellen und transgene Pflanzen enhaltend diese Sequenzen |
| DE4447387A1 (de) | 1994-12-22 | 1996-06-27 | Inst Genbiologische Forschung | Debranching-Enzyme aus Pflanzen und DNA-Sequenzen kodierend diese Enzyme |
| DE69637239T2 (de) | 1995-01-06 | 2008-05-29 | Plant Research International B.V. | Für kohlenhydratpolymere-bildende enzyme-kodierende dna-sequenzen und verfahren zur herstellung transgener pflanzen |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| DE19509695A1 (de) | 1995-03-08 | 1996-09-12 | Inst Genbiologische Forschung | Verfahren zur Herstellung einer modifizieren Stärke in Pflanzen, sowie die aus den Pflanzen isolierbare modifizierte Stärke |
| US5994627A (en) | 1995-03-31 | 1999-11-30 | Common Wealth Scientific And Industrial Research Organisation | Genetic sequences conferring nematode resistance in plants and uses therefor |
| CA2217878A1 (en) | 1995-05-05 | 1996-11-07 | National Starch And Chemical Investment Holding Corporation | Improvements in or relating to plant starch composition |
| FR2734842B1 (fr) | 1995-06-02 | 1998-02-27 | Rhone Poulenc Agrochimie | Sequence adn d'un gene de l'hydroxy-phenyl pyruvate dioxygenase et obtention de plantes contenant un gene de l'hydroxy-phenyl pyruvate dioxygenase, tolerantes a certains herbicides |
| US5712107A (en) | 1995-06-07 | 1998-01-27 | Pioneer Hi-Bred International, Inc. | Substitutes for modified starch and latexes in paper manufacture |
| US6284479B1 (en) | 1995-06-07 | 2001-09-04 | Pioneer Hi-Bred International, Inc. | Substitutes for modified starch and latexes in paper manufacture |
| EP1728441A3 (de) | 1995-09-19 | 2007-03-07 | Bayer BioScience GmbH | Pflanzen, die eine modifizierte Stärke synthetisieren, Verfahren zu ihrer Herstellung sowie modifizierte Stärke |
| GB9524938D0 (en) | 1995-12-06 | 1996-02-07 | Zeneca Ltd | Modification of starch synthesis in plants |
| DE19601365A1 (de) | 1996-01-16 | 1997-07-17 | Planttec Biotechnologie Gmbh | Nucleinsäuremoleküle aus Pflanzen codierend Enzyme, die an der Stärkesynthese beteiligt sind |
| DE19608918A1 (de) | 1996-03-07 | 1997-09-11 | Planttec Biotechnologie Gmbh | Nucleinsäuremoleküle, die neue Debranching-Enzyme aus Mais codieren |
| DE19618125A1 (de) | 1996-05-06 | 1997-11-13 | Planttec Biotechnologie Gmbh | Nucleinsäuremoleküle, die neue Debranching-Enzyme aus Kartoffel codieren |
| DE19619918A1 (de) | 1996-05-17 | 1997-11-20 | Planttec Biotechnologie Gmbh | Nucleinsäuremoleküle codierend lösliche Stärkesynthasen aus Mais |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| IL127246A0 (en) | 1996-05-29 | 1999-09-22 | Hoechst Schering Agrevo Gmbh | Nucleic acid molecules encoding enzymes from wheat which are involved in starch synthesis |
| JP2000512349A (ja) | 1996-06-12 | 2000-09-19 | パイオニア ハイ―ブレッド インターナショナル，インコーポレイテッド | 製紙における改変澱粉の代用品 |
| JP2000512348A (ja) | 1996-06-12 | 2000-09-19 | パイオニア ハイ―ブレッド インターナショナル，インコーポレイテッド | 製紙における改変澱粉の代用品 |
| AU731229B2 (en) | 1996-06-12 | 2001-03-29 | Pioneer Hi-Bred International, Inc. | Substitutes for modified starch in paper manufacture |
| US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
| US5944710A (en) | 1996-06-24 | 1999-08-31 | Genetronics, Inc. | Electroporation-mediated intravascular delivery |
| US5869326A (en) | 1996-09-09 | 1999-02-09 | Genetronics, Inc. | Electroporation employing user-configured pulsing scheme |
| GB9907461D0 (en) | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
| GB9623095D0 (en) | 1996-11-05 | 1997-01-08 | Nat Starch Chem Invest | Improvements in or relating to starch content of plants |
| US6232529B1 (en) | 1996-11-20 | 2001-05-15 | Pioneer Hi-Bred International, Inc. | Methods of producing high-oil seed by modification of starch levels |
| DE19653176A1 (de) | 1996-12-19 | 1998-06-25 | Planttec Biotechnologie Gmbh | Neue Nucleinsäuremoleküle aus Mais und ihre Verwendung zur Herstellung einer modifizierten Stärke |
| US5981840A (en) | 1997-01-24 | 1999-11-09 | Pioneer Hi-Bred International, Inc. | Methods for agrobacterium-mediated transformation |
| DE19708774A1 (de) | 1997-03-04 | 1998-09-17 | Max Planck Gesellschaft | Nucleinsäuremoleküle codierend Enzyme die Fructosylpolymeraseaktivität besitzen |
| DE19709775A1 (de) | 1997-03-10 | 1998-09-17 | Planttec Biotechnologie Gmbh | Nucleinsäuremoleküle codierend Stärkephosphorylase aus Mais |
| US6489458B2 (en) | 1997-03-11 | 2002-12-03 | Regents Of The University Of Minnesota | DNA-based transposon system for the introduction of nucleic acid into DNA of a cell |
| GB9710049D0 (en) | 1997-05-19 | 1997-07-09 | Nycomed Imaging As | Method |
| GB9718863D0 (en) | 1997-09-06 | 1997-11-12 | Nat Starch Chem Invest | Improvements in or relating to stability of plant starches |
| GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| WO1999021977A1 (en) | 1997-10-24 | 1999-05-06 | Life Technologies, Inc. | Recombinational cloning using nucleic acids having recombination sites |
| DE19749122A1 (de) | 1997-11-06 | 1999-06-10 | Max Planck Gesellschaft | Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen |
| FR2770854B1 (fr) | 1997-11-07 | 2001-11-30 | Rhone Poulenc Agrochimie | Sequence adn d'un gene de l'hydroxy-phenyl pyruvate dioxygenase et obtention de plantes contenant un tel gene, tolerantes aux herbicides |
| AU3478499A (en) | 1998-04-09 | 1999-11-01 | E.I. Du Pont De Nemours And Company | Starch r1 phosphorylation protein homologs |
| DE19820607A1 (de) | 1998-05-08 | 1999-11-11 | Hoechst Schering Agrevo Gmbh | Nucleinsäuremoleküle codierend Enzyme aus Weizen, die an der Stärkesynthese beteiligt sind |
| DE19820608A1 (de) | 1998-05-08 | 1999-11-11 | Hoechst Schering Agrevo Gmbh | Nucleinsäuremoleküle codierend Enzyme aus Weizen, die an der Stärkesynthese beteiligt sind |
| CN1309834C (zh) | 1998-05-13 | 2007-04-11 | 拜尔生物科学有限公司 | 质体adp/atp转运蛋白活性改变的转基因植物 |
| JP2002518015A (ja) | 1998-06-15 | 2002-06-25 | ナショナル スターチ アンド ケミカル インベストメント ホールディング コーポレイション | 植物および植物製品の改良またはそれらに関する改良 |
| US6750059B1 (en) | 1998-07-16 | 2004-06-15 | Whatman, Inc. | Archiving of vectors |
| US6693185B2 (en) | 1998-07-17 | 2004-02-17 | Bayer Bioscience N.V. | Methods and means to modulate programmed cell death in eukaryotic cells |
| DE19836098A1 (de) | 1998-07-31 | 2000-02-03 | Hoechst Schering Agrevo Gmbh | Pflanzen, die eine modifizierte Stärke synthetisieren, Verfahren zur Herstellung der Pflanzen, ihre Verwendung sowie die modifizierte Stärke |
| DE19836099A1 (de) | 1998-07-31 | 2000-02-03 | Hoechst Schering Agrevo Gmbh | Nukleinsäuremoleküle kodierend für eine ß-Amylase, Pflanzen, die eine modifizierte Stärke synthetisieren, Verfahren zur Herstellung der Pflanzen, ihre Verwendung sowie die modifizierte Stärke |
| DE19836097A1 (de) | 1998-07-31 | 2000-02-03 | Hoechst Schering Agrevo Gmbh | Nukleinsäuremoleküle kodierend für eine alpha-Glukosidase, Pflanzen, die eine modifizierte Stärke synthetisieren, Verfahren zur Herstellung der Pflanzen, ihre Verwendung sowie die modifizierte Stärke |
| WO2000011192A2 (en) | 1998-08-25 | 2000-03-02 | Pioneer Hi-Bred International, Inc. | Plant glutamine: fructose-6-phosphate amidotransferase nucleic acids |
| WO2000014249A1 (en) | 1998-09-02 | 2000-03-16 | Planttec Biotechnologie Gmbh | Nucleic acid molecules encoding an amylosucrase |
| DE19924342A1 (de) | 1999-05-27 | 2000-11-30 | Planttec Biotechnologie Gmbh | Genetisch modifizierte Pflanzenzellen und Pflanzen mit erhöhter Aktivität eines Amylosucraseproteins und eines Verzweigungsenzyms |
| KR20010099681A (ko) | 1998-10-09 | 2001-11-09 | 추후제출 | 나이세리아속 세균에서 가지화 효소를 코딩하는 핵산분자및 α-1,6-가지화 α-1,4-글루칸을 제조하는 방법 |
| BR9915152A (pt) | 1998-11-09 | 2001-08-07 | Planttec Biotechnologie Gmbh | Moléculas de ácido nucléico de arroz e o seu uso para a produção de amido modificado |
| US7160682B2 (en) | 1998-11-13 | 2007-01-09 | Regents Of The University Of Minnesota | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell |
| US6531648B1 (en) | 1998-12-17 | 2003-03-11 | Syngenta Participations Ag | Grain processing method and transgenic plants useful therein |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| DE19905069A1 (de) | 1999-02-08 | 2000-08-10 | Planttec Biotechnologie Gmbh | Nucleinsäuremoleküle codierend Alternansucrase |
| US7868149B2 (en) | 1999-07-20 | 2011-01-11 | Monsanto Technology Llc | Plant genome sequence and uses thereof |
| DE19926771A1 (de) | 1999-06-11 | 2000-12-14 | Aventis Cropscience Gmbh | Nukleinsäuremoleküle aus Weizen, transgene Pflanzenzellen und Pflanzen und deren Verwendung für die Herstellung modifizierter Stärke |
| US6603061B1 (en) | 1999-07-29 | 2003-08-05 | Monsanto Company | Agrobacterium-mediated plant transformation method |
| DE19937348A1 (de) | 1999-08-11 | 2001-02-22 | Aventis Cropscience Gmbh | Nukleinsäuremoleküle aus Pflanzen codierend Enzyme, die an der Stärkesynthese beteiligt sind |
| DE19937643A1 (de) | 1999-08-12 | 2001-02-22 | Aventis Cropscience Gmbh | Transgene Zellen und Pflanzen mit veränderter Aktivität des GBSSI- und des BE-Proteins |
| WO2001014569A2 (de) | 1999-08-20 | 2001-03-01 | Basf Plant Science Gmbh | Erhöhung des polysaccharidgehaltes in pflanzen |
| US6423886B1 (en) | 1999-09-02 | 2002-07-23 | Pioneer Hi-Bred International, Inc. | Starch synthase polynucleotides and their use in the production of new starches |
| GB9921830D0 (en) | 1999-09-15 | 1999-11-17 | Nat Starch Chem Invest | Plants having reduced activity in two or more starch-modifying enzymes |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1047770A1 (zh) | 2000-02-24 | 2003-03-07 | Xcyte Therapies, Inc. | 细胞的同时刺激与浓缩 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6768044B1 (en) | 2000-05-10 | 2004-07-27 | Bayer Cropscience Sa | Chimeric hydroxyl-phenyl pyruvate dioxygenase, DNA sequence and method for obtaining plants containing such a gene, with herbicide tolerance |
| GB0024550D0 (enExample) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| US6734340B2 (en) | 2000-10-23 | 2004-05-11 | Bayer Cropscience Gmbh | Monocotyledon plant cells and plants which synthesise modified starch |
| JP2004528821A (ja) | 2000-12-07 | 2004-09-24 | シンジェンタ リミテッド | 除草剤抵抗性植物 |
| WO2002079410A2 (en) | 2001-03-30 | 2002-10-10 | Basf Plant Science Gmbh | Glucan chain length domains |
| WO2002083911A1 (en) | 2001-04-12 | 2002-10-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Production of plants with increased tolerance to drought stress or with increased transpiration |
| EP1483390B1 (en) | 2001-06-12 | 2008-05-07 | Bayer CropScience AG | Transgenic plants synthesising high amylose starch |
| WO2003020763A2 (en) | 2001-08-31 | 2003-03-13 | Avidex Limited | Soluble t cell receptor |
| US7776321B2 (en) | 2001-09-26 | 2010-08-17 | Mayo Foundation For Medical Education And Research | Mutable vaccines |
| CN100509853C (zh) | 2001-10-17 | 2009-07-08 | 巴斯福种植科学有限公司 | 淀粉 |
| GB0125216D0 (en) | 2001-10-19 | 2001-12-12 | Univ Strathclyde | Dendrimers for use in targeted delivery |
| US20090100536A1 (en) | 2001-12-04 | 2009-04-16 | Monsanto Company | Transgenic plants with enhanced agronomic traits |
| EP1458879A2 (en) | 2001-12-21 | 2004-09-22 | Oxford Biomedica (UK) Limited | Method for producing a transgenic organism using a lentiviral expression vector such as eiav |
| DE10208132A1 (de) | 2002-02-26 | 2003-09-11 | Planttec Biotechnologie Gmbh | Verfahren zur Herstellung von Maispflanzen mit erhöhtem Blattstärkegehalt und deren Verwendung zur Herstellung von Maissilage |
| US7432416B2 (en) | 2002-03-27 | 2008-10-07 | Agrigenetics, Inc. | Generation of plants with improved drought tolerance |
| AU2003231048A1 (en) | 2002-04-22 | 2003-11-03 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| AU2003284388A1 (en) | 2002-11-01 | 2004-06-07 | New England Biolabs, Inc. | Organellar targeting of rna and its use in the interruption of environmental gene flow |
| NZ539226A (en) | 2002-11-09 | 2008-09-26 | Medigene Ltd | T cell receptor display |
| DK1578973T3 (da) | 2002-12-19 | 2008-11-24 | Bayer Cropscience Ag | Planteceller og planter, der syntetiserer en stivelse med foröget slutviskositet |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US20060162021A1 (en) | 2003-03-07 | 2006-07-20 | Basf Plant Science Gmbh | Enhanced amylose production in plants |
| ATE517996T1 (de) | 2003-04-09 | 2011-08-15 | Bayer Bioscience Nv | Verfahren und mittel zur erhöhung der toleranz von pflanzen gegenüber stressbedingungen |
| JP2007500514A (ja) | 2003-04-29 | 2007-01-18 | パイオニア ハイ−ブレッド インターナショナル， インコーポレイテッド | 新規なグリホセートｎ−アセチルトランスフェラーゼ（ｇａｔ）遺伝子 |
| EP1629102A4 (en) | 2003-05-22 | 2007-10-17 | Syngenta Participations Ag | MODIFIED STARCH, THEIR USE AND METHOD FOR THE PRODUCTION THEREOF |
| US7985739B2 (en) | 2003-06-04 | 2011-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced sleeping beauty transposon system and methods for using the same |
| US7754945B2 (en) | 2003-06-24 | 2010-07-13 | Agrigenetics Inc. | Generation of plants with improved drought tolerance |
| ES2559828T3 (es) | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| BRPI0412582A (pt) | 2003-07-31 | 2006-09-19 | Toyo Boseki | plantas produtoras de ácido hialurÈnico |
| NZ581166A (en) | 2003-09-15 | 2011-06-30 | Protiva Biotherapeutics Inc | Polyethyleneglycol-modified lipid compounds and uses thereof |
| WO2005030942A1 (en) | 2003-09-30 | 2005-04-07 | Bayer Cropscience Gmbh | Plants with reduced activity of a class 3 branching enzyme |
| US20070011777A1 (en) | 2003-09-30 | 2007-01-11 | Claus Frohberg | Plants with increased activity of a class 3 branching enzyme |
| GB0325379D0 (en) | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| CA2557843C (en) | 2004-03-05 | 2015-06-02 | Bayer Cropscience Gmbh | Plants with reduced activity of a starch phosphorylating enzyme |
| AR048025A1 (es) | 2004-03-05 | 2006-03-22 | Bayer Cropscience Gmbh | Plantas con actividad aumentada de una enzima fosforilante del almidon |
| AR048026A1 (es) | 2004-03-05 | 2006-03-22 | Bayer Cropscience Gmbh | Procedimientos para la identificacion de proteinas con actividad enzimatica fosforiladora de almidon |
| AR048024A1 (es) | 2004-03-05 | 2006-03-22 | Bayer Cropscience Gmbh | Plantas con actividad aumentada de distintas enzimas fosforilantes del almidon |
| EP2319932B2 (en) | 2004-04-30 | 2016-10-19 | Dow AgroSciences LLC | Novel herbicide resistance gene |
| SI1771206T1 (en) | 2004-05-05 | 2018-06-29 | Silence Therapeutics Gmbh | LIPID LIPID COMPLEXES AND THEIR USE |
| EP1756278B1 (en) | 2004-05-19 | 2008-09-17 | MediGene Ltd. | Method of improving t cell receptors |
| ATE417065T1 (de) | 2004-05-19 | 2008-12-15 | Medigene Ltd | Hochaffiner ny-eso-t-zellen-rezeptor |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| WO2005121348A1 (en) | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| DE102004029763A1 (de) | 2004-06-21 | 2006-01-05 | Bayer Cropscience Gmbh | Pflanzen, die Amylopektin-Stärke mit neuen Eigenschaften herstellen |
| DK1791865T3 (da) | 2004-06-29 | 2010-11-01 | Immunocore Ltd | Celler der udtrykker en modificeret T-cellerecptor |
| JP4772045B2 (ja) | 2004-07-16 | 2011-09-14 | アメリカ合衆国 | Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン |
| PT1786908E (pt) | 2004-08-18 | 2010-04-29 | Bayer Cropscience Ag | Plantas com um aumento da actividade da enzima de fosforilação do amido r3 nos plastídeos |
| WO2006032538A1 (en) | 2004-09-23 | 2006-03-30 | Bayer Cropscience Gmbh | Methods and means for producing hyaluronan |
| GB0422877D0 (en) | 2004-10-14 | 2004-11-17 | Univ Glasgow | Bioactive polymers |
| AU2005298784B2 (en) | 2004-10-29 | 2011-06-09 | Bayer Cropscience Nv. | Stress tolerant cotton plants |
| EP1672075A1 (en) | 2004-12-17 | 2006-06-21 | Bayer CropScience GmbH | Transformed plant expressing a dextransucrase and synthesizing a modified starch |
| JP5292572B2 (ja) | 2004-12-27 | 2013-09-18 | サイレンス・セラピューティクス・アーゲー | コーティングされた脂質複合体およびそれらの使用 |
| EP1679374A1 (en) | 2005-01-10 | 2006-07-12 | Bayer CropScience GmbH | Transformed plant expressing a mutansucrase and synthesizing a modified starch |
| JP2006304779A (ja) | 2005-03-30 | 2006-11-09 | Toyobo Co Ltd | ヘキソサミン高生産植物 |
| EP1707632A1 (de) | 2005-04-01 | 2006-10-04 | Bayer CropScience GmbH | Phosphorylierte waxy-Kartoffelstärke |
| EP1710315A1 (de) | 2005-04-08 | 2006-10-11 | Bayer CropScience GmbH | Hoch Phosphat Stärke |
| EP1885754B1 (en) | 2005-05-25 | 2011-02-09 | Immunocore Ltd. | T cell receptors which specifically bind to vygfvracl-hla-a24 |
| US8143192B2 (en) | 2005-06-15 | 2012-03-27 | Bayer Cropscience N.V. | Methods for increasing the resistance of plants to hypoxic conditions |
| AR054174A1 (es) | 2005-07-22 | 2007-06-06 | Bayer Cropscience Gmbh | Sobreexpresion de sintasa de almidon en vegetales |
| WO2007039316A1 (en) | 2005-10-05 | 2007-04-12 | Bayer Cropscience Ag | Improved methods and means for producings hyaluronan |
| CA2624592C (en) | 2005-10-05 | 2016-07-19 | Bayer Cropscience Ag | Gfat-expressing plants with increased hyaluronan production |
| AU2006298962A1 (en) | 2005-10-05 | 2007-04-12 | Bayer Cropscience Ag | Plants with an increased production of hyaluronan II |
| WO2007048046A2 (en) | 2005-10-20 | 2007-04-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of filovirus gene expression |
| CN101346393B (zh) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| US8158856B2 (en) | 2006-03-21 | 2012-04-17 | Bayer Cropscience Nv | Stress resistant plants |
| EP2992875A1 (en) | 2006-04-20 | 2016-03-09 | Silence Therapeutics GmbH | Lipoplex formulations for specific delivery to vascular endothelium |
| US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| JP2008078613A (ja) | 2006-08-24 | 2008-04-03 | Rohm Co Ltd | 窒化物半導体の製造方法及び窒化物半導体素子 |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| US20100099858A1 (en) | 2006-09-28 | 2010-04-22 | Mirkin Chad A | Maximizing Oligonucleotide Loading on Gold Nanoparticle |
| WO2008038002A2 (en) | 2006-09-29 | 2008-04-03 | Medigene Limited | T cell therapies |
| WO2008064289A2 (en) | 2006-11-21 | 2008-05-29 | The Samuel Roberts Noble Foundation, Inc. | Biofuel production methods and compositions |
| NZ587060A (en) | 2007-12-31 | 2012-09-28 | Nanocor Therapeutics Inc | Rna interference for the treatment of heart failure |
| EP3095869B1 (en) | 2008-04-14 | 2019-06-19 | BASF Agricultural Solutions Seed US LLC | Mutated hydroxyphenylpyruvate dioxygenase, dna sequence and isolation of plants which are tolerant to hppd inhibitor herbicides |
| PL2279254T3 (pl) | 2008-04-15 | 2017-11-30 | Protiva Biotherapeutics Inc. | Nowe preparaty lipidowe do dostarczania kwasów nukleinowych |
| US8575305B2 (en) | 2008-06-04 | 2013-11-05 | Medical Research Council | Cell penetrating peptides |
| EP2309980A1 (en) | 2008-07-08 | 2011-04-20 | S.I.F.I. Societa' Industria Farmaceutica Italiana | Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
| JP6087504B2 (ja) | 2008-11-07 | 2017-03-01 | マサチューセッツ インスティテュート オブ テクノロジー | アミノアルコールリピドイドおよびその使用 |
| JP6069755B2 (ja) | 2008-11-24 | 2017-02-01 | ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー | 高親和性ｔ細胞受容体およびその用途 |
| GB2465749B (en) | 2008-11-25 | 2013-05-08 | Algentech Sas | Plant cell transformation method |
| WO2010096488A1 (en) | 2009-02-17 | 2010-08-26 | The Regents Of The University Of California | Method of reducing acetylation in plants to improve biofuel production |
| WO2010129602A2 (en) | 2009-05-04 | 2010-11-11 | Fred Hutchinson Cancer Research Center | Cocal vesiculovirus envelope pseudotyped retroviral vectors |
| WO2011000108A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein b |
| JP5766188B2 (ja) | 2009-07-01 | 2015-08-19 | プロチバ バイオセラピューティクス インコーポレイティッド | 固形腫瘍に治療剤を送達するための脂質製剤 |
| WO2011008730A2 (en) | 2009-07-13 | 2011-01-20 | Somagenics Inc. | Chemical modification of small hairpin rnas for inhibition of gene expression |
| WO2011028929A2 (en) | 2009-09-03 | 2011-03-10 | The Regents Of The University Of California | Nitrate-responsive promoter |
| SG10201407996PA (en) | 2009-12-23 | 2015-01-29 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| US8372951B2 (en) | 2010-05-14 | 2013-02-12 | National Tsing Hua University | Cell penetrating peptides for intracellular delivery |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| WO2011148194A1 (en) | 2010-05-28 | 2011-12-01 | Oxford Biomedica (Uk) Ltd | Delivery of lentiviral vectors to the brain |
| EP2609135A4 (en) | 2010-08-26 | 2015-05-20 | Massachusetts Inst Technology | POLY (BETA AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9499592B2 (en) | 2011-01-26 | 2016-11-22 | President And Fellows Of Harvard College | Transcription activator-like effectors |
| PL2691443T3 (pl) | 2011-03-28 | 2021-08-30 | Massachusetts Institute Of Technology | Sprzężone lipomery i ich zastosowania |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| US20120295960A1 (en) | 2011-05-20 | 2012-11-22 | Oxford Biomedica (Uk) Ltd. | Treatment regimen for parkinson's disease |
| SI3392270T1 (sl) | 2011-09-15 | 2020-12-31 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni MAGE |
| EP3692794A1 (en) | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| BR112014007078B1 (pt) | 2011-09-26 | 2018-03-06 | Sumitomo Chemical Company, Limited | Composição e método de controle de doença de plantas |
| US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
| DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
| US20130185823A1 (en) | 2012-01-16 | 2013-07-18 | Academia Sinica | Mesoporous silica nanoparticle-mediated delivery of dna into arabidopsis root |
| EP2814967A1 (en) | 2012-02-17 | 2014-12-24 | Keygene N.V. | Improving drought resistance in plants: upl3 |
| JP2015515530A (ja) | 2012-04-18 | 2015-05-28 | アローヘッド リサーチ コーポレイション | インビボ核酸送達のためのポリ（アクリラート）ポリマー |
| JP6251734B2 (ja) | 2012-05-03 | 2017-12-27 | フレッド ハッチンソン キャンサー リサーチ センター | 親和性増強型ｔ細胞受容体およびその作製方法 |
| HUE064187T2 (hu) | 2012-05-25 | 2024-02-28 | Cellectis | Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására |
| CA2878856A1 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating car t cells |
| EP3494997B1 (en) | 2012-07-25 | 2019-09-18 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
| SG11201500423TA (en) | 2012-07-27 | 2015-02-27 | Univ Illinois | Engineering t-cell receptors |
| EP3763810A3 (en) | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| EP2898075B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| EP4299741A3 (en) | 2012-12-12 | 2024-02-28 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| IL239344B2 (en) | 2012-12-12 | 2024-06-01 | Broad Inst Inc | Systems engineering, methods and optimal guiding components for sequence manipulation |
| ES2701749T3 (es) | 2012-12-12 | 2019-02-25 | Broad Inst Inc | Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| PL2896697T3 (pl) | 2012-12-12 | 2016-01-29 | Broad Inst Inc | Projektowanie systemów, sposoby i optymalizowane kompozycje kierujące do manipulacji sekwencją |
| JP2016505256A (ja) | 2012-12-12 | 2016-02-25 | ザ・ブロード・インスティテュート・インコーポレイテッ | 配列操作のためのＣＲＩＳＰＲ−Ｃａｓ成分系、方法および組成物 |
| WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| MX378463B (es) | 2013-02-26 | 2025-03-10 | Memorial Sloan Kettering Cancer Center | Composiciones y usos de las mismas para inmunoterapia. |
| US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
| WO2014172606A1 (en) | 2013-04-19 | 2014-10-23 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
| CN105378067A (zh) | 2013-05-13 | 2016-03-02 | 塞勒克提斯公司 | 工程化用于免疫治疗的高活性t细胞的方法 |
| AU2014273490B2 (en) | 2013-05-29 | 2019-05-09 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system |
| WO2014204723A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions |
| BR122021009076B1 (pt) | 2013-06-17 | 2024-02-15 | The Broad Institute Inc. | Vetor viral contendo molécula(s) de ácido nucleico heterólogo, composição, uso e métodos do mesmo |
| AU2014281026B2 (en) | 2013-06-17 | 2020-05-28 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
| BR112015031608A2 (pt) | 2013-06-17 | 2017-08-22 | Massachusetts Inst Technology | Aplicação e uso dos sistemas crispr-cas, vetores e composições para direcionamento e terapia hepáticos |
| EP3011033B1 (en) | 2013-06-17 | 2020-02-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| ES2767318T3 (es) | 2013-06-17 | 2020-06-17 | Broad Inst Inc | Suministro, modificación y optimización de sistemas, métodos y composiciones para generar modelos y actuar sobre enfermedades y trastornos de células posmitóticas |
| CN105492611A (zh) | 2013-06-17 | 2016-04-13 | 布罗德研究所有限公司 | 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物 |
| AU2014287397B2 (en) | 2013-07-10 | 2019-10-10 | President And Fellows Of Harvard College | Orthogonal Cas9 proteins for RNA-guided gene regulation and editing |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| EP3058091B1 (en) | 2013-10-18 | 2020-03-25 | The Broad Institute, Inc. | Spatial and cellular mapping of biomolecules in situ by high-throughput sequencing |
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| US9074199B1 (en) | 2013-11-19 | 2015-07-07 | President And Fellows Of Harvard College | Mutant Cas9 proteins |
| WO2015082080A1 (en) | 2013-12-05 | 2015-06-11 | Silence Therapeutics Gmbh | Means for lung specific delivery |
| SG10201804977UA (en) | 2013-12-12 | 2018-07-30 | Broad Inst Inc | Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Particle Delivery Components |
| WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| EP3080259B1 (en) | 2013-12-12 | 2023-02-01 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| SG10201804975PA (en) | 2013-12-12 | 2018-07-30 | Broad Inst Inc | Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders |
| EP3653703A1 (en) | 2013-12-12 | 2020-05-20 | The Broad Institute, Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
| WO2015089462A1 (en) * | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing |
| CA2932439A1 (en) * | 2013-12-12 | 2015-06-18 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes |
| US10557146B2 (en) | 2014-01-21 | 2020-02-11 | The Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences | Modified plants |
| US20170088845A1 (en) | 2014-03-14 | 2017-03-30 | The Regents Of The University Of California | Vectors and methods for fungal genome engineering by crispr-cas9 |
| JP5937635B2 (ja) | 2014-03-28 | 2016-06-22 | ファナック株式会社 | 電磁接触器の溶着検出機能を有するモータ駆動装置 |
| CN104004782B (zh) | 2014-05-16 | 2016-06-08 | 安徽省农业科学院水稻研究所 | 一种延长水稻生育期的育种方法 |
| EP3149168B1 (en) | 2014-05-27 | 2021-09-22 | The Broad Institute, Inc. | High-throughput assembly of genetic elements |
| WO2016049258A2 (en) | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
| EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
| WO2016094872A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
| WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
| CA2970370A1 (en) | 2014-12-24 | 2016-06-30 | Massachusetts Institute Of Technology | Crispr having or associated with destabilization domains |
| JP6956705B2 (ja) | 2015-04-10 | 2021-11-02 | フェルダン・バイオ・インコーポレーテッド | 標的真核細胞のサイトゾルへのポリペプチドカーゴの形質導入効率を改善するためのポリペプチドベースのシャトル剤、その使用、それと関連する方法及びキット |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| EP3596207B1 (en) | 2017-03-15 | 2023-12-20 | The Broad Institute, Inc. | Novel cas13b orthologues crispr enzymes and systems |
| WO2019005886A1 (en) * | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS |
| EP3645054A4 (en) | 2017-06-26 | 2021-03-31 | The Broad Institute, Inc. | CRISPR / CAS-ADENINE DESAMINASE COMPOSITIONS, TARGETED NUCLEIC ACID EDITING SYSTEMS AND METHODS |
| KR102338449B1 (ko) * | 2017-09-21 | 2021-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 |
-
2018
- 2018-09-21 KR KR1020207015382A patent/KR102338449B1/ko active Active
- 2018-09-21 WO PCT/US2018/052247 patent/WO2019060746A1/en not_active Ceased
- 2018-09-21 KR KR1020207008394A patent/KR20200066616A/ko not_active Ceased
- 2018-09-21 CN CN201880074422.XA patent/CN111511388A/zh active Pending
- 2018-09-21 AU AU2018338318A patent/AU2018338318B2/en active Active
- 2018-09-21 US US16/649,170 patent/US11618896B2/en active Active
- 2018-09-21 JP JP2020516525A patent/JP2020535802A/ja active Pending
- 2018-09-21 EP EP18859627.4A patent/EP3684397A4/en active Pending
- 2018-09-21 CA CA3073848A patent/CA3073848A1/en active Pending
-
2020
- 2020-04-29 AU AU2020202810A patent/AU2020202810B2/en active Active
- 2020-05-13 US US15/930,478 patent/US11685916B2/en active Active
-
2021
- 2021-09-21 JP JP2021152800A patent/JP2022000041A/ja active Pending
-
2023
- 2023-03-22 AU AU2023201781A patent/AU2023201781B2/en active Active
- 2023-06-20 JP JP2023100415A patent/JP2023134462A/ja active Pending
-
2024
- 2024-09-03 JP JP2024151114A patent/JP2025023878A/ja active Pending
- 2024-11-07 AU AU2024259800A patent/AU2024259800A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170211142A1 (en) | 2015-10-22 | 2017-07-27 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025048512A1 (ko) * | 2023-08-30 | 2025-03-06 | 주식회사 제노헬릭스 | 제한효소를 이용한 rna 라이브러리 제작 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023201781A1 (en) | 2023-06-15 |
| JP2023134462A (ja) | 2023-09-27 |
| AU2024259800A1 (en) | 2024-11-28 |
| AU2020202810B2 (en) | 2021-06-10 |
| AU2023201781A2 (en) | 2023-07-27 |
| CN111511388A (zh) | 2020-08-07 |
| KR20200066616A (ko) | 2020-06-10 |
| JP2022000041A (ja) | 2022-01-04 |
| KR20200064168A (ko) | 2020-06-05 |
| US11685916B2 (en) | 2023-06-27 |
| JP2020535802A (ja) | 2020-12-10 |
| AU2018338318B2 (en) | 2022-12-22 |
| EP3684397A4 (en) | 2021-08-18 |
| US20210009986A1 (en) | 2021-01-14 |
| EP3684397A1 (en) | 2020-07-29 |
| WO2019060746A1 (en) | 2019-03-28 |
| AU2020202810A1 (en) | 2020-05-21 |
| JP2025023878A (ja) | 2025-02-18 |
| US11618896B2 (en) | 2023-04-04 |
| CA3073848A1 (en) | 2019-03-28 |
| AU2023201781B2 (en) | 2024-08-08 |
| AU2018338318A1 (en) | 2020-04-30 |
| US20200291382A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102338449B1 (ko) | 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 | |
| US20250215408A1 (en) | Systems methods, and compositions for targeted nucleic acid editing | |
| KR102678809B1 (ko) | 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물 | |
| KR102761791B1 (ko) | 표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법 | |
| EP3625342B1 (en) | Systems, methods, and compositions for targeted nucleic acid editing | |
| US20210130800A1 (en) | Systems, methods, and compositions for targeted nucleic acid editing | |
| US20200248169A1 (en) | Crispr/cas-cytidine deaminase based compositions, systems, and methods for targeted nucleic acid editing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A302 | Request for accelerated examination | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20200528 Application number text: 1020207008394 Filing date: 20200323 |
|
| PA0201 | Request for examination | ||
| PA0302 | Request for accelerated examination |
Patent event date: 20200528 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200710 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20201230 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210531 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20210907 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20211208 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20211208 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |